Objective-Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community.
A lterations in mineral metabolism, including hyperphosphatemia, vitamin D insufficiency, and elevated parathyroid hormone (PTH) levels, are frequently present in chronic kidney disease (CKD) and substantially contribute to the high prevalence of cardiovascular morbidity and mortality observed in these patients. 1 Fibroblast growth factor-23 (FGF23) is a bone-derived circulating hormone that directly controls serum levels of phosphate, 1,25-dihydroxy vitamin D 3 , and PTH and may therefore affect cardiovascular risk. [2] [3] [4] [5] [6] High serum FGF23 levels in CKD are linked to adverse outcomes such as increased mortality in patients receiving hemodialysis 7, 8 and mortality and cardiovascular events in patients with coronary artery disease. 9 Similarly, we and others recently reported that higher FGF23 levels, both in CKD and in subjects with normal renal function, are associated with cardiovascular risk factors such as vascular dysfunction, atherosclerosis, and left ventricular hypertrophy. 10 -14 Putative pathogenic pathways of FGF23 in cardiovascular disease development remain unknown.
Phylogenic and sequence analyses have shown that FGF23 shares common structural and biological features with FGF19 and FGF21, which are members of the FGF19 subfamily. 15 The FGF19 subfamily has emerged as a set of novel factors that regulate diverse metabolic processes. 16 These FGFs are secreted factors that act systemically, in contrast to other FGFs that mainly have autocrine or paracrine functions, and require ␣-Klotho or ␤-Klotho in addition to canonical FGF receptors for their action. [17] [18] [19] [20] [21] Importantly, both FGF19 and FGF21 have been implied in the regulation of lipid and glucose metabolism. [22] [23] [24] [25] [26] Because of the central role of FGF23 in mineral metabolism and its common structural features with FGF19 and FGF21, we aimed to test whether FGF23 associates with an adverse lipid and glucose metabolism that predisposes to an increased cardiovascular risk in 2 independent cohorts of elderly individuals.
Methods The Osteoporotic Fractures in Men Study Cohort
The Osteoporotic Fractures in Men Study (MrOS) is an international multicenter prospective epidemiological investigation of elderly men. The Swedish part consists of 3014 men aged 69 to 80 years. 27 The participants were randomly selected from population registries and invited by mail in the cities of Uppsala (nϭ999), Malmö (nϭ1005), and Göteborg (nϭ1010). To be eligible for the study, the subject had to be able to walk without aid, and subjects with bilateral hip replacements were excluded. There were no other exclusion criteria. At the clinic visit, participants completed questionnaires about their medical history, current medication used, and lifestyle characteristics. Informed consent was obtained for all subjects, and the study was approved by the local ethics committees at Uppsala (ethical approval number Ups 01-057), Malmö (LU-693-00), and Göteborg (Gbg M 014-01) universities and conducted in accordance with the guidelines in the Declaration of Helsinki.
Serum parameters reflecting fat mass and glucose homeostasis were analyzed only in the Göteborg part of the Swedish MrOS. Thus, participants from other Swedish study sites were not included in the present study. Baseline characteristics were, as previously shown, similar among the 3 study sites. 28 Thus, for the present study, only subjects from the Göteborg part (75.3Ϯ3.2 years of age, nϭ1010) were included. Of the 1010 subjects in the MrOS cohort, 28 were missing FGF23 measurements (nϭ28), 7 were missing biochemistry measurements (nϭ7), and 11 were missing lipid measurements (nϭ11). In all, 46 subjects were excluded, and 964 subjects were included in subsequent analyses. Of those, 582 (60.4%) used at least 1 medication, as follows: diabetes treatment, 79 (8.2%); high thyroid treatment, 3 (0.3%); low thyroid treatment, 17 (1.8%); osteoporosis treatment, 9 (0.9%); stroke treatment, 43 (4.5%); Parkinson disease treatment, 6 (0.6%); high blood pressure treatment, 328 (34.0%); myocardial infarction treatment (including statins), 122 (12.7%); angina treatment, 101 (10.5%); congestive heart failure treatment, 84 (8.7%); chronic obstructive pulmonary disease, asthma, or emphysema treatment, 58 (6.0%); prostatis treatment, 62 (6.4%); glaucoma treatment, 37 (3.8%); medication for arthritis or joint pain, 87 (9.0%); and currently treated for kidney stones, 3 (0.3%).
Basic Investigation
Height was measured using a wall-mounted stadiometer, and weight was measured to the nearest 0.1 kg. All measurements were performed by the same staff. Body mass index (BMI) was calculated as weight (kg)/height (m 2 ).
Serum Biochemistries
Plasma and serum samples were collected at 8 AM after at least 10 hours of fasting and nonsmoking and were immediately stored at Ϫ80°C. Cystatin C was analyzed with polyclonal antibodies against human cystatin C and measured by immunoturbidimetry (Cystatin C Immunoparticles, Dako Denmark A/S, Glostrup, Denmark). Estimated glomerular filtration rate (eGFR) was calculated using the following estimate: glomerular filtration rateϭ79.901ϫ(cystatin C) Ϫ1.4389 . This proxy for glomerular filtration rate has good precision, good linearity, and strong correlation with iohexol clearance (R 2 ϭ0.956). 29 
Serum Lipids
Serum lipid analyses were performed on a Konelab 20 autoanalyzer (Thermo Electron Corporation, Vantaa, Finland). Total cholesterol and triglyceride levels were determined by fully enzymatic techniques. High-density lipoprotein (HDL) was determined after precipitation of apolipoprotein B (apoB)-containing lipoproteins with magnesium sulfate and dextran sulfate. Low-density lipoprotein (LDL) was calculated using the Friedewald formula. apoB and apolipoprotein A1 (apoA1) were determined by immunoprecipitation enhanced by polyethylene glycol at 340 nm. Interassay CVs were below 5% for all Konelab analyses.
Serum Levels of Insulin and Glucose
Fasting plasma glucose was quantitated by an enzymatic method on a Modular instrument (Roche, Stockholm, Sweden) with an interassay CV of less than 4%. Homeostasis model assessment (HOMA) index was calculated as the product of fasting serum insulin level (microunits per milliliter) and fasting plasma glucose level (millimoles per liter) divided by 22.5. 30 
Body Composition and Fat Mass
Total and trunk fat mass and lean mass were assessed by dual x-ray absorptiometry (DXA) analysis, using a Hologic QDR 4500/A-Delphi (Hologic, Waltham, Mass). The CVs for the measurements ranged from 0.5% to 3%, depending on the application.
The Prospective Investigation of the Vasculature in Uppsala Seniors Cohort
Participants from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study were aged 70 and living in the community of Uppsala, Sweden. They were invited by mail within 1 month of their 70th birthday in a randomized order from April 2001 to June 2004. Of the 2025 subjects invited, 1016 subjects were investigated. 31 An analysis of nonparticipants showed the present sample to be representative of the total cohort regarding cardiovascular disorders and drug intake. 31 Of 1016 subjects, 13 were missing FGF23 measurements, 42 were missing biochemistry, 4 were missing lipid measurements, and 11 were missing waist circumference or waist-to-hip ratio (WHR). In total, 70 subjects were excluded, and 946 subjects were included in subsequent analyses. All participants answered a questionnaire about their medical history, smoking habits, and regular medication and were investigated under standardized conditions in the morning after an overnight fast. No medication or smoking was allowed after midnight. In total, 662 (70.0%) subjects used any type of medication (in monotherapy or in combination), including hypertensive medication, 291 (30.8%); bronchdilators, 57 (6.0%); nitroglycerin, 29 (3.1%); ␤-blockers, 199 (21.0%); calcium antagonists, 110 (11.6%); diuretics, 115 (12.2%); angiotensin-converting enzyme (ACE) inhibitors, 81 (8.6%); angiotensin receptor blockers, 77 (8.1%); statins, 140 (14.8%); other lipid lowering drugs, 12 (1.3%); warfarin, 28 (3.0%); acetylsalicylic acid (ASA), 171 (18.1%); antiarrhythmics, 1 (0.1%); insulin, 18 (1.9%); and oral antidiabetics, 55 (5.8%). Hypertension was defined as noninvasively measured supine systolic blood pressureՆ140 mm Hg, diastolic blood pres-sureՆ90 mm Hg, or current use of antihypertensive medication. The ethics committee of Uppsala University approved the study, and the participants gave informed consent.
Basic Investigation
Height, weight, and BMI were recorded as for the MrOS cohort. The circumference of the abdomen (waist circumference) was measured at the umbilical level and the hip circumference at the trochanter level. WHR was then calculated.
Serum Biochemistries
Plasma cystatin C (reagent 1014, Gentian, Moss, Norway) and phosphate (reagent 7D71-30) analyses were performed on an Architect Ci8200 analyzer (Abbott Laboratories, Abbott Park, Ill). eGFR was determined as described for the MrOS. PTH levels were analyzed using the Immulite 2000 Intact PTH Assay (Diagnostic Products Corp, Los Angeles, Calif). The LIAISON 25(OH)D 3 assay (DiaSorin Inc, Saluggia, Italy) was performed on a Liaison analyzer according to the manufacturer's instructions. Leptin and adiponectin were analyzed with double-antibody radioimmunoassays (Linco Research, St. Louis, Mo). Total CV for leptin was 4.7% at both low (2 to 4 ng/mL) and high (10 to 15 ng/mL) levels, and for adiponectin the total CV was 15.2% at low (2 to 4 g/mL) and 8.8% at high (26 to 54 g/mL) levels. High-sensitivity C-reactive protein was measured by an ultrasensitive particle enhanced immunoturbidimetric assay (Orion Diagnostica, Espoo, Finland) on a Konelab 20 autoanalyzer (Thermo Clinical Labsystems, Espoo, Finland). The interassay CV was 3.2%.
All other routine serum biochemistries were measured at the Department of Clinical Chemistry at Uppsala University Hospital.
Serum Lipids
Serum total cholesterol, triglycerides, and HDL were assayed by enzymatic techniques. LDL was calculated by the Friedewald formula. apoA1 and apoB were determined by a 2-site immunoradiometric assay, using commercial kits from Pharmacia (Uppsala, Sweden).
Insulin Resistance, Diabetes, and the Metabolic Syndrome
Serum insulin was measured by an enzymatic-immunologic assay (Boehringer Mannheim). HOMA insulin resistance index was defined as in MrOS 30 and was not evaluated in subjects on insulin treatment. Diabetes mellitus was defined as a self-reported history of diabetes or fasting blood glucose of 6.2 mmol/L or above.
Metabolic syndrome was defined by the National Cholesterol Education Program/Adult Treatment Panel III criteria. 32 Three of the following 5 criteria should be fulfilled: blood pressure Ͼ130/ 85 mm Hg or antihypertensive treatment, fasting blood glucose Ͼ5.6 mmol/L, serum triglycerides Ͼ1.7 mmol/L, waist circumference Ͼ102 cm in men and Ͼ88 cm in women, HDL-cholesterol Ͻ1.0 mmol/L in men and Ͻ1.3 in women.
Body Composition and Fat Mass
Total fat mass, trunk fat mass, and lean mass were assessed by DXA analysis (DPX Prodigy, Lunar Corp, Madison, Wis) on average 2 years after baseline investigation in 898 of 1016 cohort members. By triple measurements in 15 subjects, the precision error of the DXA measurements in our laboratory has been calculated to be 1.5% for total fat mass and 1.0% for total lean mass.
Serum FGF23
FGF23 was measured in both cohorts using an ELISA (Kainos Laboratories International; Tokyo, Japan). 33 This second-generation, 2-site, monoclonal antibody ELISA recognizes only the biologically active, intact FGF23. 33 The assay has a lower limit of detection of 3 pg/mL and intra-and interassay CVs of less than 5%, and it was the most sensitive among 3 different ELISAs for FGF23 measurements. 34 
Statistical Analyses
Initially, the distributional properties of all baseline variables were examined, and nonnormally distributed variables (triglycerides, HDL, leptin, calcium, PTH, and FGF23) were log-transformed before being used in subsequent analyses. Linear relationships were investigated using linear regression models, and standardized ␤-values are given for all analyses. All models were defined a priori, and the variables included were chosen based on known associations with the outcome variable or FGF23.
Relationships between FGF23 and clinical markers of general obesity (weight and BMI), central obesity (waist circumference and WHR), and body composition were evaluated in 2 models: adjusted for age and gender and adjusted for age, gender, and known FGF23-regulatory variables and factors of mineral metabolism (serum phosphate, albumin, calcium, 25(OH)D 3 , PTH, and eGFR).
Relationships between FGF23 and serum lipids (total cholesterol, triglycerides, HDL, LDL, apoA1, apoB, and leptin) were examined in 3 sets of models: a crude model; a model adjusted for age, gender, and BMI; and a model adjusted for age, gender, BMI, serum phosphate, albumin, calcium, 25(OH)D 3 , PTH, and eGFR.
Finally, we investigated whether FGF23 levels could predict the fulfillment of the National Cholesterol Education Program metabolic syndrome criteria 32 using logistic regression.
Probability values Ͻ0.05 from 2-sided tests were considered statistically significant. SAS 9.2 (SAS Institute Inc) was used for all calculations.
Results
Clinical characteristics and serum biochemistries for MrOS and PIVUS cohorts are presented in Table 1 . The same variables are presented over FGF23 tertiles in Supplemental  Tables I and II , available online at http://atvb.ahajournals.org. After exclusion of participants with missing data for any variable, 964 and 946 subjects were included in subsequent analysis in MrOS and PIVUS, respectively. Median serum FGF23 was 42.1 pg/mL (interquartile range, 33.1 to 53.7 pg/mL) in MrOS and 42.3 pg/mL (interquartile range, 33.5 to 54.0 pg/mL) in PIVUS. FGF23 levels were not influenced by gender (PϾ0.05).
FGF23, Anthropomorphic Measurements of Obesity and Fat Mass
In both cohorts, a 1-SD increase in log FGF23 was associated with 7% to 20% higher body weight and 7% to 17% higher BMI ( Table 2) , translating into a 3% increase in body weight and BMI for a 10% increase in FGF23. In PIVUS, a 1-SD increase in log FGF23 was associated with 9% to 10% higher waist circumference and 6% to 7% higher WHR (central obesity determined only in PIVUS; Table 2 ), equivalent to a 2% increase in waist circumference and WHR for a 10% increase in FGF23.
The relationship between FGF23 and overweight (BMIՆ26 as defined by the WHO criteria) was analyzed. In total, 471 (48.9%) and 542 (57.3%) were classified as overweight in MrOS and PIVUS, respectively. In MrOS, a 1-SD increase in log FGF23 was associated with an increased risk for overweight both in crude and multivariate adjusted models (OR 1.30, CI 1.14 to 1.49; OR 1.38, CI 1.19 to 1.59, respectively). We found no significant evidence for this association in PIVUS when modeling FGF23 as a continuous variable. However, in both cohorts, individuals in the highest FGF23 tertile were at a significantly higher risk for overweight than those in the lowest tertile ( Figure 1) .
As supported by anthropomorphic measurements, FGF23 was associated with total body fat mass, trunk fat mass (Table  2) , and fat mass in arms and legs (data not shown), as determined by DXA. In both cohorts, a 1-SD increase in log FGF23 was associated with 7% to 16% higher total body fat mass and 9% to 18% higher trunk fat mass ( Table 2) .
In MrOS, a 10% increase in FGF23 translated into a 4% increase in total body fat mass and trunk fat mass and 3% higher body fat. FGF23 explained 2% and 3% of the variations in total fat mass and trunk fat mass, respectively.
FGF23, Serum Lipids, Leptin, and Adiponectin
A 1-SD increase in log FGF23 was associated with 7% to 22% and 7% to 19% lower HDL and apoA1, respectively. In contrast, a corresponding 11% to 14% increase in triglycerides was observed (Table 3) . These associations were significant and essentially unaltered in crude and multivariateadjusted models in both cohorts (Table 3 ). In MrOS, a 10% increase in log FGF23 corresponded to 4% to 5% lower HDL and apoA1 and a 3% increase in triglycerides. FGF23 explained 5%, 3%, and 2% of the variations in HDL, apoA1, and triglycerides, respectively. There was no significant association between FGF23 and LDL or apoB1 (data not shown). Finally, a 1-SD increase in log FGF23 was associated with 9% to 12% higher leptin; however, this relationship was nonsignificant in multivariate-adjusted models (Table 3) . Importantly, the association between FGF23 and fat mass remained significant but was attenuated when leptin was added to multivariate model 3 ( Table 2) .
Furthermore, in multivariate models, FGF23 was inversely related to serum adiponectin (analyzed in PIVUS only) ( Table 3 ). FGF23, in addition to BMI, calcium, and eGFR, was also retained as a variable significantly associated with adiponectin in a post hoc stepwise regression model (data not shown).
FGF23, Fasting Glucose, Insulin, and HOMA Index
A 1-SD increase in log FGF23 was associated with 8% to 12% higher insulin and HOMA index in both cohorts; however, it was statistically nonsignificant in multivariable adjusted models. We found no association between FGF23 and fasting glucose (data not shown).
FGF23 and the Metabolic Syndrome
We evaluated a potential role of FGF23 in the metabolic syndrome because of its link to dyslipidemia and increased fat mass. On the basis of the updated National Cholesterol Education Program criteria, 32 the metabolic syndrome was diagnosed in 23.3% (nϭ220) of all PIVUS subjects (all components of the metabolic syndrome were recorded in PIVUS only). These participants had significantly higher FGF23 levels compared with subjects without the metabolic syndrome (median FGF23, 46.4 versus 41.2 pg/mL; PϽ0.05). Similarly, FGF23 levels were higher in subjects fulfilling the National Cholesterol Education Program triglyceride criteria (Ͼ1.7 mmol/L) compared with those who did not (median Values are mean (standard deviation) for normally distributed continuous variables, median (10th to 90th percentiles) for nonnormally distributed variables, and n (%) for categorical variables.
FGF23, 46.9 versus 41.5 pg/mL; PϽ0.01). In MrOS, both subjects fulfilling the triglyceride and HDL criteria (Ͻ1.0 mmol/L in men and Ͻ1.3 mmol/L in women) had significantly higher FGF23 level compared with those who did not (median FGF23, 44.2 versus 41.4, PϽ0.001, and 43.1 versus 41.4 pg/mL, PϽ0.01, respectively). We did not find any significant evidence for the relationship between FGF23 levels and the number of metabolic syndrome criteria met (data not shown). Hence, FGF23 may represent the burden of the metabolic syndrome risk factors rather than the clustering of these factors.
A 1-SD increase in log FGF23 was associated with a 21% (95% CI, 4% to 41%) increased risk of having the metabolic syndrome, although it was borderline significant in multivariate adjusted models (Table 4 ). FGF23 was also associated with an increased risk of fulfilling the triglyceride and HDL criteria of the metabolic syndrome (Table 4 ). Subjects within the highest FGF23 tertile were at a nearly 2-fold increased risk of having the metabolic syndrome ( Figure 2 ).
Subgroup Analyses
All associations remained significant and unaltered after removal of subjects with diabetes (MrOS: nϭ220; PIVUS: nϭ111), and FGF23 did not predict the presence of diabetes (data not shown). A multiplicative interaction term between FGF23 and diabetes was significant for FGF23 associations with HDL and apoA1 in PIVUS but not in MrOS. In stratified analyses, the crude association between FGF23 and lipid variables were essentially consistent in subjects with diabetes compared with subjects without; however, it was nonsignificant in some multivariate models, likely because of loss of power (data not shown).
The associations also remained significant after removal of subjects with previous cardiovascular disease (MrOS, nϭ304; PIVUS, nϭ155), and there was no evidence for an interaction between FGF23 and previous cardiovascular disease (data not shown).
Finally, we did not find any significant evidence for an interaction between FGF23 and diminished renal function (glomerular filtration rate, Ͻ60 mL/min per 1.73 m 2 ).
Discussion
In the current study, we evaluated the relationship between FGF23 and metabolic cardiovascular risk factors in 2 independent community-based, cross-sectional cohorts of elderly individuals. We report on novel associations between serum FGF23 levels and higher BMI, larger waist circumference, elevated triglycerides, lower HDL cholesterol and apoA1, and increased total and trunk fat mass.
This study is important from the point of view that FGF23 may be a biomarker of cardiovascular disease in CKD. The current understanding of FGF23 and cardiovascular risk is incomplete and mainly relates to the role of FGF23 in mineral metabolism. As such, changes in serum phosphate, PTH, or vitamin D levels, factors that are regulated by FGF23, are associated with increased cardiovascular morbidity and mortality. 35 Similarly, FGF23 was suggested as a biomarker of phosphate-induced cardiovascular toxicity in CKD, possibly explaining its link to increased mortality risk in CKD patients receiving hemodialysis. 7, 8 We provide evidence that the relationship between FGF23 and cardiovascular risk may, in part, be mediated through classical risk factors beyond mineral metabolism, that is, obesity and dyslipidemia. Note that the strongest associations were found between FGF23 and central obesity. Values are ␤-values for 1-SD increase in log FGF23 (95% confidence intervals). *PϽ0.05, †PϽ0.01, ‡PϽ0.001, §PϽ0.0001. Statistically significant results are in boldface.
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There may be several explanatory factors for the observed association among FGF23, fat mass, and dyslipidemia. FGF23 could exert indirect metabolic effects because of variations in mineral metabolism or, alternatively, indicate
as-yet-unidentified end-organ effects of FGF23 beyond kidneys and parathyroid glands. In support for the first hypothesis, elevated PTH levels and vitamin D insufficiency are associated with increased fat mass and the metabolic syndrome. 36, 37 Additionally, Fgf23-null mice experience both cardiovascular calcifications and disturbed glucose and lipid homeostasis 38 ; however, these metabolic alterations and calcification phenotype are largely normalized after genetic and dietary alterations in phosphate and vitamin D pathways. 39 -41 It should also be noted that phosphate-lowering therapy with sevelamer in CKD patients leads to an improved blood lipid profile, including higher HDL and lower LDL, 42 which speculatively could be attributed to a reduction in net serum phosphate balance in addition to intestinal binding of bile salts. Collectively, given the critical role of phosphate in generation of ATP and protein production, the link between FGF23 and fat mass may represent a regulatory mechanism to coordinate systemic phosphate metabolism with the presence of long-term energy stores.
On the other hand, it is tempting to infer parallels to other bone-derived factors, such as osteocalcin, which exerts profound effect on glucose homeostasis, insulin sensitivity, and fat metabolism. 43, 44 In this regard, the FGF23-related growth factors FGF19 and FGF21 directly control fat mass and glucose metabolism in rodents 23, 26 and our findings should prompt mechanistic studies addressing potential similar functions of FGF23. It should, however, be pointed out that the clinical significance of FGF19 and FGF21 in humans remains unclear, although a higher FGF21 level is associated with obesity, type 2 diabetes mellitus, and the metabolic syndrome. [45] [46] [47] A recent report showed that leptin directly stimulates FGF23 expression in bone, 48 further accentuating the biological relevance of this report. In support for leptin regulation of FGF23, the association between FGF23 and fat mass was attenuated when adjusting for serum leptin and FGF23 correlated to serum leptin. FGF23 was also inversely related to adiponectin, which is highly expressed in adipose tissue 49 and protects against endothelial damage and subsequent cardiovascular disease. 50, 51 This may be yet another explanatory factor for FGF23 association to vascular dysfunction.
Because there is a strong interplay between fat mass and diabetes, we examined whether diabetes modified the relationship of FGF23 to fat mass. FGF23 did not predict the presence of diabetes or related to HOMA index or blood glucose in multivariate models. Although the relationship FGF23 to HDL and apoA1 was somewhat strengthened in subjects with diabetes in PIVUS, diabetes is not a major modifier of the relationship of FGF23 to fat mass and dyslipidemia.
Although we found no gender difference in FGF23 level, its association to fat mass and lipid metabolism was consistently stronger in male than in female subjects. At this point, it remains elusive whether this represents a true gender difference or is due to other confounding factors, but it is possible that the effects of FGF23 may be influenced by sex hormones.
This study has several strengths. Our data are validated in 2 large, independent cohorts with inclusion of both genders, and we have as far as possible adjusted for relevant confounders. Fat mass and serum biochemistries were determined by accurate quantification methods. Potential limitations are lack of adjustments for dietary intake, especially of phosphate and vitamin D. The study cohorts represent only elderly whites with normal renal function. Because FGF23 levels increase dramatically with declining renal function, [52] [53] [54] we cannot conclude whether these elevated levels of FGF23 will still be associated with an adverse lipid profile in CKD or in patients of other ethnic backgrounds. Interestingly, black and Hispanic patients on hemodialysis have a survival advantage compared with whites [55] [56] [57] [58] and also have lower FGF23 levels, 7 yet caution must be taken when generalizing our results to these populations. Finally, causal relationships between FGF23, fat mass, and serum lipids cannot be evaluated in a cross-sectional study design. Regardless, the importance of this study is evidenced by the established roles of other FGFs in regulation of lipid metabolism and fat mass, as well as the emerging concept of FGF23 as a biomarker for cardiovascular risk.
In conclusion, circulating FGF23 is associated with increased fat mass and dyslipidemia in humans, supporting a novel link between FGF23 and cardiovascular risk.
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Figure 2.
The relationship between FGF23 and the metabolic syndrome in the PIVUS study. Subjects in the highest FGF23 tertile (white column: tertile 1 as referent) had an increased risk for the presence of the metabolic syndrome. Left, Crude model. Right, Multivariate model adjusted for age, gender, BMI, phosphate, albumin, calcium, 25(OH)D, PTH, and eGFR. FGF23 tertile 1Յ33.1 pg/mL; FGF23 tertile 2ϭ33.1 to 53.7 pg/mL; FGF23 tertile 3Ͼ53.7 pg/mL. ***PϽ0.001.
